Bladder cancer is the sixth most common cancer in the United States. Patients with locally advanced or metastatic disease have poor long-term survival, especially those who have progressed after chemotherapy and immunotherapy. A new agent, enfortumab vedotin-ejfv (PADCEV, Astellas Pharma US, Inc.), ...